Roche en­lists Monte Rosa for can­cer, neu­ro dis­cov­ery deal with $50M up­front

Roche is forg­ing a new part­ner­ship with a start­up fo­cused on pro­tein degra­da­tion.

The multi­na­tion­al phar­ma com­pa­ny an­nounced Tues­day it is pay­ing $50 mil­lion up­front to team up with Monte Rosa Ther­a­peu­tics and its slate of “mol­e­c­u­lar glue” pro­grams that it ar­gues can tar­get pro­teins cen­tral to the degra­da­tion process. If every­thing comes to fruition, Roche could end up spend­ing more than $2 bil­lion in down­stream biobucks, ac­cord­ing to a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER